Literature DB >> 33208970

New lung-cancer drugs extend survival times.

Michael Eisenstein.   

Abstract

Entities:  

Keywords:  Cancer; Medical research; Personalized medicine

Mesh：

Substances：

Year:  2020        PMID： 33208970     DOI： 10.1038/d41586-020-03154-y

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  4 in total

1.  Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.

Authors:  D Ross Camidge; Rafal Dziadziuszko; Solange Peters; Tony Mok; Johannes Noe; Malgorzata Nowicka; Shirish M Gadgeel; Parneet Cheema; Nick Pavlakis; Filippo de Marinis; Byoung Chul Cho; Li Zhang; Denis Moro-Sibilot; Ting Liu; Walter Bordogna; Bogdana Balas; Barbara Müller; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2019-03-20       Impact factor: 15.609

2.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

Authors:  Jonathan M Ostrem; Ulf Peters; Martin L Sos; James A Wells; Kevan M Shokat
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

3.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Authors:  Suresh S Ramalingam; Johan Vansteenkiste; David Planchard; Byoung Chul Cho; Jhanelle E Gray; Yuichiro Ohe; Caicun Zhou; Thanyanan Reungwetwattana; Ying Cheng; Busyamas Chewaskulyong; Riyaz Shah; Manuel Cobo; Ki Hyeong Lee; Parneet Cheema; Marcello Tiseo; Thomas John; Meng-Chih Lin; Fumio Imamura; Takayasu Kurata; Alexander Todd; Rachel Hodge; Matilde Saggese; Yuri Rukazenkov; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2019-11-21       Impact factor: 91.245

4.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245
  4 in total
  1 in total

1.  Fbxo45-mediated NP-STEP46 degradation via K6-linked ubiquitination sustains ERK activity in lung cancer.

Authors:  Qian Wang; Ci Xu; Renjie Cai; Weishu An; Haihua Yuan; Ming Xu
Journal:  Mol Oncol       Date:  2022-08-05       Impact factor: 7.449
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.